arrow
D

David A. Rizzieri

ut md anderson cancer center
H指数:64
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study

探索在门诊环境中为造血细胞移植受者进行葡萄糖酸洗必泰(CHG)沐浴的可行性、挑战和支持需求的观点:一项定性研究

2025-09-190
PRE
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

接受维奈克拉联合阿扎胞苷治疗的患者与仅接受阿扎胞苷治疗的患者,其结局比较,按高龄和急性髓系白血病复合模型分层。

Leukemia
IF13.4
2025-09-050
OAAI
Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

嵌合抗原受体T细胞疗法治疗高级别B细胞淋巴瘤NOS

2025-07-220
PRE
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
2024-08-142
OAAI
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
2023-11-177
OAAI
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
LEUKEMIA
IF13.4
2023-11-079
PRE
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
2023-07-288
OAAI
Single-cell landscape analysis unravels molecular programming of the human B cell in chronic GVHD
2023-06-085
OA
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
2023-04-2817
OAAI
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group
HELIYON
IF3.6
2023-04-017
OAAI
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

Fostamatinib抑制SYK在预防和治疗慢性移植物抗宿主病中的I期试验

2023-03-0110
OAAI
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
2023-02-0920
OAAI
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia
2022-06-0620
OA
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis
2022-04-2115
OAAI
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Research
2022-04-0110
OAAI
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
2022-02-0111
OAAI
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

单倍体与同胞,无关或脐带血造血细胞移植治疗急性淋巴细胞白血病

2022-01-1148
OAAI